ReviewClinical and experimental medicine2026
GRP78 in viral pneumonia: dual regulatory mechanisms and translational prospects.
Review in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Glucose-regulated protein 78 (GRP78), a core molecular chaperone governing the endoplasmic reticulum (ER) stress response, exerts dual regulatory effects during the pathogenesis of viral pneumonia. Beyond serving as a critical cofactor that promotes viral invasion and replication, GRP78 functions as an indispensable protective chaperone that preserves pulmonary cellular homeostasis and attenuates lung injury. This review characterizes two distinct subcellular localizations of GRP78 in viral pneumonia, namely ER-resident GRP78 and cell surface GRP78 (csGRP78), and systematically summarizes its dual regulatory mechanisms. Specifically, csGRP78 mediates viral adhesion and internalization, whereas ER-GRP78 promotes viral replication and aggravates pulmonary inflammation by modulating ER stress and the unfolded protein response. Meanwhile, GRP78 alleviates pulmonary tissue damage via suppressing lung cell apoptosis and restraining excessive ERS activation. Moreover, this review provides a comprehensive overview of advances in GRP78-targeted therapeutic strategies. The covered therapeutic modalities include small-molecule inhibitors, biological macromolecular drugs, indirect regulatory compounds, and natural products. This review also elaborates their specific molecular targets, core mechanisms, and preclinical findings. Additionally, the current research trends, existing limitations, and future perspectives of GRP78-related investigations are critically discussed. This review aims to clarify the central regulatory role of GRP78 in viral pneumonia, providing theoretical basis and innovative research directions for the precision targeted therapy of viral pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.